Full Press Release Details
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer.
GLUE
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Key Takeaway: Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Price reaction · baseline $16.02 (2026-03-13 close) · 1 other GLUE headline(s) in the window, move may be shared
day 0 close
+2.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+67%
120-day peak, hindsight
Typical move
13.3%
average across 9 past catalysts
Cash runway
~41 mo
Minimal dilution risk
Lead asset
MRT-2359
Phase 2 · Castration-Resistant Prostate Cancer (CRPC)